SCHOTT Pharma invests over USD 60 million to expand vial production in Lebanon, Pennsylvania

  • Schott Pharma inaugurated expanded vial production in Lebanon, Pennsylvania, adding new lines for standard vials and sterile ready-to-use glass vials.
  • Investment exceeded USD 60 million, largely funded by BARDA, aimed at strengthening US domestic primary-packaging supply for critical medicines.
  • Expansion lifts annual capacity for core vials, while more than tripling local output for high-value solutions.
  • Site added upgraded converting lines, infrastructure modernization, automation, supporting production of adaptiQ ready-to-use vials, EVERIC pure vials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schott Pharma AG & Co. KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202606031456BIZWIRE_USPR_____20260603_BW634326) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.